Effects of interleukin-11 antagonist on pulmonary fibrosis in mice

doi:10.12047/j.cjap.6047.2021.015

Abstract

Abstract: Objective: To investigate the effects of interleukin 11 (IL-11) antagonist on bleomycin (BLM)-induced pulmonary fibrosis in mice. Methods: C57BL/6 mice were randomly divided into the control group, IL-11 antagonist group, BLM group, and BLM + IL-11 antagonist group (30 in each group). Mice in the BLM group and BLM + IL-11 antagonist group were injected with BLM at the dose of 1.5 mg/kg to induce pulmonary fibrosis. The IL-11 antagonist IL-11 Rα FC (2.5 mg/kg) was administered via the tail vein to the mice in the IL-11 antagonist group and BLM + IL-11 antagonist group every 3 days from the BLM injection. The survival status of the mice was observed. On the 21^st day after modeling, HE staining, Masson staining, and Ashcroft score were used to evaluate the degree of pulmonary fibrosis. The content of hydroxyproline (HYP) in lung tissue was determined by the alkaline hydrolysis method. The gene and protein expressions of Collagen I, Collagen III, and α-SMA in lung tissues were detected by real-time PCR and Western blot, respectively. TGF-β1 content in lung tissue was determined by enzyme-linked immunosorbent assay. Results: Compared with the control group, BLM reduced the survival rate, destructed the lung tissue, and increased the gene and protein expressions of Collagen I, Collagen III, α-SMA, and the content of TGF-β1 in lung tissue. While, IL-11 Rα Fc treatment improved the survival rate of BLM-induced pulmonary mice, reduced pathological changes, and hydroxyproline content in lung tissue. IL-11 Rα Fc also reduced Collagen I, Collagen III, and α-SMA mRNA and protein expression in the lungs of BLM-treated mice, as well as TGF-β1 content. Conclusion: The IL-11 antagonist alleviates BLM-induced pulmonary fibrosis in mice, which provides a new idea for the clinical treatment of pulmonary fibrosis.

Key words: pulmonary fibrosis, interleukin 11, bleomycin, collagen deposition, mice

CLC Number:

R563.9

WU Li-xun, WU Xiang. Effects of interleukin-11 antagonist on pulmonary fibrosis in mice[J]. CJAP, 2021, 37(3): 308-312.

References 18

[1]	Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis [J]. N Engl J Med, 2018, 378(19): 1811-1823.
[2]	Martinez FJ, Collard HR, Pardo A, et al. Idiopathic pulmonary fibrosis [J]. Nat Rev Dis Primers, 2017, 3: 17074.
[3]	Schafer S, Viswanathan S, Widjaja AA, et al. IL-11 is a crucial determinant of cardiovascular fibrosis [J]. Nature, 2017, 552(7683): 110-115.
[4]	Zhang X, Kiapour N, Kapoor S, et al. IL-11 antagonist suppresses Th17 cell-mediated neuroinflammation and demyelination in a mouse model of relapsing-remitting multiple sclerosis [J]. Clin Immunol, 2018, 197: 45-53.
[5]	张荔茗, 张君, 张英, 等. 特发性肺纤维化小鼠肺内IL-11及其受体表达 [J]. 中南大学学报(医学版), 2018, 43(10): 1083-1088.
[6]	Ng B, Dong J, D'Agostino G, et al. Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis [J]. Sci Transl Med, 2019, 11(511): eaaw1237.
[7]	Raish M, Ahmad A, Ahmad Ansari M, et al. Sinapic acid ameliorates bleomycin-induced lung fibrosis in rats [J]. Biomed Pharmacother, 2018, 108: 224-231.
[8]	Peng L, Wen L, Shi QF, et al. Scutellarin ameliorates pulmonary fibrosis through inhibiting NF-κB/NLRP3-mediated epithelial-mesenchymal transition and inflammation [J]. Cell Death Dis, 2020, 11(11): 978.
[9]	Carrington R, Jordan S, Pitchford SC, et al. Use of animal models in IPF research [J]. Pulm Pharmacol Ther, 2018, 51: 73-78.
[10]	Della Latta V, Cecchettini A, Del Ry S, et al. Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions [J]. Pharmacol Res, 2015, 97: 122-130.
[11]	Al-Tamari HM, Dabral S, Schmall A, et al. FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis [J]. EMBO Mol Med, 2018, 10(2): 276-293.
[12]	Cipolla E, Fisher AJ, Gu H, et al. IL-17A deficiency mitigates bleomycin-induced complement activation during lung fibrosis [J]. FASEB J, 2017, 31(12): 5543-5556.
[13]	Li Y, Jiang D, Liang J, et al. Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44 [J]. J Exp Med, 2011, 208(7): 1459-1471.
[14]	Li X, Lu C, Liu S, et al. Synthesis and discovery of a drug candidate for treatment of idiopathic pulmonary fibrosis through inhibition of TGF-beta1 pathway [J]. Eur J Med Chem, 2018, 157: 229-247.
[15]	Spagnolo P, Kropski JA, Jones MG, et al. Idiopathic pulmonary fibrosis: Disease mechanisms and drug development [J]. Pharmacol Ther, 2020: 107798.
[16]	Tzortzaki EG, Antoniou KM, Zervou MI, et al. Effects of antifibrotic agents on TGF-beta1, CTGF and IFN-gamma expression in patients with idiopathic pulmonary fibrosis [J]. Respir Med, 2007, 101(8): 1821-1829.
[17]	Wynn TA. Cellular and molecular mechanisms of fibrosis [J]. J Pathol, 2008, 214(2): 199-210.
[18]	Dong Y, Geng Y, Li L, et al. Blocking follistatin-like 1 attenuates bleomycin-induced pulmonary fibrosis in mice [J]. J Exp Med, 2015, 212(2): 235-252.